Elizabeth Laws leads Sanofi’s inflammation and immunology development pipeline to test the first oral TNFR1 inhibitor for rheumatoid arthritis and psoriasis.
Explore how emerging in vitro systems — built from primary cells, cocultures, and vascularized tissues — are improving translational research outcomes.